Your browser doesn't support javascript.
loading
A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.
Cercek, Andrea; Gendel, Vyacheslav; Jabbour, Salma; Moore, Dirk; Chen, Chunxia; Nosher, John; Capanu, Marinela; Chou, Joanne F; Boucher, Taryn; Kemeny, Nancy; Carpizo, Darren R.
Afiliação
  • Cercek A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gendel V; Department of Radiology, Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
  • Jabbour S; Rutgers Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ, 08903, USA.
  • Moore D; Department of Radiation Oncology, Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
  • Chen C; Department of Biostatistics, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Nosher J; Department of Biostatistics, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Capanu M; Department of Radiology, Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
  • Chou JF; Rutgers Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ, 08903, USA.
  • Boucher T; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kemeny N; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carpizo DR; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Curr Treat Options Oncol ; 18(7): 42, 2017 07.
Article em En | MEDLINE | ID: mdl-28608276
ABSTRACT
OPINION STATEMENT Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos de Ítrio / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Compostos Radiofarmacêuticos / Embolização Terapêutica / Neoplasias Hepáticas / Microesferas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos de Ítrio / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Compostos Radiofarmacêuticos / Embolização Terapêutica / Neoplasias Hepáticas / Microesferas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article